MRD-guided ibrutinib-venetoclax significantly improved outcomes for previously untreated patients with CLL compared with ibrutinib or chemoimmunotherapy.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
CLL Society has put together a learning activity that will help those with CLL / SLL learn about the role of MRD testing, gain an understanding of how it can be used as part of your disease management plan, and empower you to discuss its potential use with your healthcare provider.
CLL Society has put together a learning activity that will help those with CLL / SLL learn about the role of MRD testing, gain an understanding of how it can be used as part of your disease management plan, and empower you to discuss its potential use with your healthcare provider.
CLL Society has put together a learning activity that will help those with CLL / SLL learn about the role of MRD testing, gain an understanding of how it can be used as part of your disease management plan, and empower you to discuss its potential use with your healthcare provider.
Undetectable measurable (minimal) residual disease (uMRD) has strong prognostic significance in CLL and may, in the future, guide the duration of therapy.
Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
